Stoke Therapeutics (STOK) Peer Comparison

$33.09

$-0.37 (-1.11%)

As on 26-Aug-2026 16:00EDT

Market cap

$2,084 Mln

Revenue (TTM)

$28 Mln

P/E Ratio

--

P/B Ratio

6

Div. Yield

0 %

Edit

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	2,084	16,614	17,326	13,400	12,305
Revenue ($ Mln)	28	1,054	2,782	2,436	670
Net Profit ($ Mln)	-207.90	755.85	491.50	860.62	-319.95
Net Margin (%)	-753.60	71.69	17.67	35.33	-47.79
RoE (%)	-59.57	--	110.09	42.98	-71.14
Price to Earnings	--	19.38	36.49	17.01	--
Price-To-Book	6.03	10.05	39.43	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	27.59	1,054.37	2,782.29	2,435.92	669.50
Cost of Revenue	4.23	103.47	1,982.07	85.67	19.14
Gross Profit	184.42	588.53	760.62	2,236.43	829.45
Operating Expenses	246.74	841.45	216.81	1,378.74	895.93
Operating Profit (EBIT)	-223.38	109.45	583.40	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-209.18	101.11	598.92	1,035.47	-252.08
Provision for Tax	-1.28	-654.74	107.42	174.84	20.05
Profit after Tax (Net Income)	-207.90	755.85	491.50	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	345.55	1,435.90	433.86	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	6.49	384.48	187.89	288.55	1,362.63
Current Liabilities	41.93	464.70	1,435.43	361.93	283.35
Total Liabilities	418.43	1,302.02	1,975.47	2,844.42	1,385.30

Assets ($ Mln)

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	71.43	895.24	1,006.90	1,243.41	440.60
Current Assets	322.54	1,389.84	1,050.29	1,250.82	1,671.41
Total Assets	418.43	1,302.02	1,975.47	2,844.42	1,385.30
Total Debt*	2.68	449.89	120.10	165.93	864.07
Net Current Assets	280.61	0.00	-385.14	888.90	1,388.07

Cashflow ($ Mln)

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	45.59	51.77	713.22	884.27	179.55
Cash Flow from Investing Activities	-186.81	-8.15	-31.14	350.44	-129.29
Cash from Financing Activities	97.39	34.89	-860.39	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-2.34	-30.01	53.56	32.82	-0.17
ROE (%)	-59.57	163.18	110.09	42.98	-71.14
ROA (%)	-48.40	26.53	15.64	29.32	-16.12
EBIT Margin (%)	-759.71	5.73	21.13	31.04	-0.77
Net Margin (%)	-753.60	71.69	17.67	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	-86.20	114.85	24.67	9.23	12.22
EBIT Growth (%)	-489.84	136.39	18.70	-3.99	93.17
Net Profit Growth (%)	-496.12	378.76	17.50	42.89	-115.58
EPS Growth (%)	-499.12	353.27	26.84	50.42	-73.87
Book Value Growth (%)	-8.81	816.12	164.02	-0.70	-13.57

Valuation Ratios

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-269.17	-59.76	36.06	15.79	-2,869.63
Price / Book Value	5.26	-80.42	35.44	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-307.25	-121.54	28.08	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.01	0.05	0.00	0.00	0.09
Current Ratio	7.69	2.99	0.73	3.46	5.90
Quick Ratio	7.69	2.32	0.73	3.38	5.90
Interest Coverage	-4,546.39	1.62	--	--	-1.72

Operating Efficiency Ratios

	Stoke Therapeutics (STOK)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	31.60	21.25	15.88	13.74	1.28
Asset Turnover	0.06	0.37	0.89	0.83	0.34
Receivable days	8.52	85.52	50.42	43.48	1.50
Inventory Days	--	1,056.70	--	96.17	--
Payable days	--	331.01	6.26	147.97	221.81
Cash Conversion Cycle	--	811.21	--	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly